HUTCHMED closes GSK license for KRAS-EGFR antibody drug outside China

HUTCHMED (China) Limited has completed the exclusive development and license agreement with GSK plc, transferring worldwide rights for HMPL-A830 to the pharmaceutical major. The deal, which closed on October 20, 2026, follows the initial announcement made on September 3, 2026, and required the completion of customary closing conditions, including antitrust regulatory reviews.

The agreement grants a GSK subsidiary the exclusive rights to develop and commercialize HMPL-A830 in all regions except Mainland China, Hong Kong, Macau, and Taiwan. The transaction involves HUTCHMED Limited, a subsidiary of the listed company, and a subsidiary of GSK. HUTCHMED remains listed on the Nasdaq, AIM, and HKEX exchanges under the ticker HCM or 13.